Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

EDWARD R DABROWSKI

Allopathic & Osteopathic Physicians Physical Medicine & Rehabilitation

NPI
1548230253
CMS profile
205382
Location
ROSEVILLE, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$36,163.47

124 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

Page 3 of 3; records 101–124 of 124 matching records. This page contains 24 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

EDWARD R DABROWSKI

NPI 1548230253 · CMS profile ID 205382

Allopathic & Osteopathic Physicians / Physical Medicine & Rehabilitation

ROSEVILLE, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–124 of 124 matching records. This page contains 24 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1548230253?year=2022&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
EDWARD R DABROWSKI, NPI 1548230253, CMS profile ID 205382. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–124 of 124 matching records. This page contains 24 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1548230253?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). EDWARD R DABROWSKI, NPI 1548230253, CMS profile ID 205382. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–124 of 124 matching records. This page contains 24 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1548230253?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
EDWARD R DABROWSKI, NPI 1548230253, CMS profile ID 205382, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–124 of 124 matching records. This page contains 24 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1548230253?year=2022&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

124 matching records · $36,163.47 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 124 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–124 of 124.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Supernus Pharmaceuticals, Inc. $13.9703/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 952936583 CMS
Amgen Inc. $15.8403/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939376003 CMS
Ipsen Biopharmaceuticals, Inc $15.8503/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893390937 CMS
JAZZ PHARMACEUTICALS INC. $20.8603/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951384935 CMS
Ipsen Biopharmaceuticals, Inc $1,290.0003/16/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893385879 CMS
Merz Pharmaceuticals, LLC $128.3103/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943789853 CMS
Supernus Pharmaceuticals, Inc. $18.5303/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 952936577 CMS
PTC Therapeutics, Inc. $540.0003/10/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 960178975 CMS
Allergan, Inc. $2.3003/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 889868891 CMS
Merz Pharmaceuticals, LLC $41.8003/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943789851 CMS
PTC Therapeutics, Inc. $13.3003/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 960178971 CMS
Philips Electronics North America Corporation $25.5402/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945626773 CMS
Ipsen Biopharmaceuticals, Inc $13.7902/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893388711 CMS
Allergan, Inc. $9.9802/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 889868887 CMS
Allergan, Inc. $15.7402/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 889868889 CMS
SK Life Science, Inc. $20.2802/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940687977 CMS
Supernus Pharmaceuticals, Inc. $20.5202/15/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 952936571 CMS
Biohaven Pharmaceutical Holding Company Ltd. $13.4102/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923568789 CMS
UCB, Inc. $19.9002/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908133593 CMS
Allergan, Inc. $124.0202/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 889868885 CMS
Neurelis, Inc. $13.5202/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950148725 CMS
BOSTON SCIENTIFIC CORPORATION $121.2301/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893697983 CMS
Ipsen Biopharmaceuticals, Inc $15.2401/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893387095 CMS
Ipsen Biopharmaceuticals, Inc $11.8001/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893386875 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $48,299.50 165
PY2020 $6,709.87 49
PY2021 $10,040.94 72
PY2022 $36,163.47 124
PY2023 $26,042.89 116
PY2024 $18,619.13 124
PY2025 $21,326.27 67

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $30,894.58 69
PY2024 Principal investigator $43,596.37 20
PY2023 Principal investigator $6,906.45 4
PY2022 Recipient $15,750.00 1
PY2022 Principal investigator $51,599.20 9
PY2021 Principal investigator $39,827.25 6
PY2020 Principal investigator $16,339.04 5
PY2019 Principal investigator $35,974.08 6

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

69 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Ipsen Pharma SAS $1,463.00 12/31/2025 Non-covered Recipient Entity
Michigan Center Of Medical Research
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184307559
Principal investigator 1 Ipsen Pharma SAS $1,350.00 11/24/2025 Non-covered Recipient Entity
Michigan Center Of Medical Research
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184307509
Principal investigator 1 Ipsen Pharma SAS $500.00 11/24/2025 Non-covered Recipient Entity
Michigan Center Of Medical Research
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184307513
Principal investigator 1 Ipsen Pharma SAS $500.00 11/24/2025 Non-covered Recipient Entity
Michigan Center Of Medical Research
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184307517
Principal investigator 1 Ipsen Pharma SAS $500.00 11/24/2025 Non-covered Recipient Entity
Michigan Center Of Medical Research
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184307519
Principal investigator 1 Ipsen Pharma SAS $500.00 11/24/2025 Non-covered Recipient Entity
Michigan Center Of Medical Research
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184307521
Principal investigator 1 Ipsen Pharma SAS $1,200.00 11/03/2025 Non-covered Recipient Entity
Michigan Center Of Medical Research
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184307511
Principal investigator 1 Ipsen Pharma SAS $1,500.00 11/03/2025 Non-covered Recipient Entity
Michigan Center Of Medical Research
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184307515
Principal investigator 1 Ipsen Pharma SAS $2,000.00 09/19/2025 Covered Recipient Teaching Hospital
Beaumont Health - Grosse Pointe
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305525
Principal investigator 1 Ipsen Pharma SAS $1,989.68 08/08/2025 Covered Recipient Teaching Hospital
Beaumont Health - Grosse Pointe
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305521
Principal investigator 1 Ipsen Pharma SAS $2,275.63 08/08/2025 Non-covered Recipient Entity
Michigan Center Of Medical Research
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184307493
Principal investigator 1 Ipsen Pharma SAS $160.00 06/30/2025 Covered Recipient Teaching Hospital
Beaumont Health - Grosse Pointe
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305491
Principal investigator 1 Ipsen Pharma SAS $22.00 06/30/2025 Covered Recipient Teaching Hospital
Beaumont Health - Grosse Pointe
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305493
Principal investigator 1 Ipsen Pharma SAS $160.00 06/30/2025 Covered Recipient Teaching Hospital
Beaumont Health - Grosse Pointe
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305495
Principal investigator 1 Ipsen Pharma SAS $41.00 06/30/2025 Covered Recipient Teaching Hospital
Beaumont Health - Grosse Pointe
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305497
Principal investigator 1 Ipsen Pharma SAS $52.00 06/30/2025 Covered Recipient Teaching Hospital
Beaumont Health - Grosse Pointe
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305499
Principal investigator 1 Ipsen Pharma SAS $50.00 06/30/2025 Covered Recipient Teaching Hospital
Beaumont Health - Grosse Pointe
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305501
Principal investigator 1 Ipsen Pharma SAS $22.00 06/30/2025 Covered Recipient Teaching Hospital
Beaumont Health - Grosse Pointe
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305503
Principal investigator 1 Ipsen Pharma SAS $120.00 06/30/2025 Covered Recipient Teaching Hospital
Beaumont Health - Grosse Pointe
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305505
Principal investigator 1 Ipsen Pharma SAS $75.00 06/30/2025 Covered Recipient Teaching Hospital
Beaumont Health - Grosse Pointe
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305507
Principal investigator 1 Ipsen Pharma SAS $50.00 06/30/2025 Covered Recipient Teaching Hospital
Beaumont Health - Grosse Pointe
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305509
Principal investigator 1 Ipsen Pharma SAS $120.00 06/30/2025 Covered Recipient Teaching Hospital
Beaumont Health - Grosse Pointe
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305511
Principal investigator 1 Ipsen Pharma SAS $131.00 06/30/2025 Covered Recipient Teaching Hospital
Beaumont Health - Grosse Pointe
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305513
Principal investigator 1 Ipsen Pharma SAS $131.00 06/30/2025 Covered Recipient Teaching Hospital
Beaumont Health - Grosse Pointe
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305515
Principal investigator 1 Ipsen Pharma SAS $41.00 06/30/2025 Covered Recipient Teaching Hospital
Beaumont Health - Grosse Pointe
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305517
Principal investigator 1 Ipsen Pharma SAS $52.00 06/30/2025 Covered Recipient Teaching Hospital
Beaumont Health - Grosse Pointe
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305519
Principal investigator 1 Ipsen Pharma SAS $147.00 05/21/2025 Covered Recipient Teaching Hospital
Beaumont Health - Grosse Pointe
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305467
Principal investigator 1 Ipsen Pharma SAS $147.00 05/21/2025 Covered Recipient Teaching Hospital
Beaumont Health - Grosse Pointe
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305469
Principal investigator 1 Ipsen Pharma SAS $51.00 05/21/2025 Covered Recipient Teaching Hospital
Beaumont Health - Grosse Pointe
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305471
Principal investigator 1 Ipsen Pharma SAS $147.00 05/21/2025 Covered Recipient Teaching Hospital
Beaumont Health - Grosse Pointe
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305473
Principal investigator 1 Ipsen Pharma SAS $51.00 05/21/2025 Covered Recipient Teaching Hospital
Beaumont Health - Grosse Pointe
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305475
Principal investigator 1 Ipsen Pharma SAS $51.00 05/21/2025 Covered Recipient Teaching Hospital
Beaumont Health - Grosse Pointe
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305477
Principal investigator 1 Ipsen Pharma SAS $147.00 05/21/2025 Covered Recipient Teaching Hospital
Beaumont Health - Grosse Pointe
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305479
Principal investigator 1 Ipsen Pharma SAS $147.00 05/21/2025 Covered Recipient Teaching Hospital
Beaumont Health - Grosse Pointe
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305481
Principal investigator 1 Ipsen Pharma SAS $51.00 05/21/2025 Covered Recipient Teaching Hospital
Beaumont Health - Grosse Pointe
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305483
Principal investigator 1 Ipsen Pharma SAS $51.00 05/21/2025 Covered Recipient Teaching Hospital
Beaumont Health - Grosse Pointe
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305485
Principal investigator 1 Ipsen Pharma SAS $51.00 05/21/2025 Covered Recipient Teaching Hospital
Beaumont Health - Grosse Pointe
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305487
Principal investigator 1 Ipsen Pharma SAS $147.00 05/21/2025 Covered Recipient Teaching Hospital
Beaumont Health - Grosse Pointe
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305489
Principal investigator 1 Ipsen Pharma SAS $2,175.88 04/04/2025 Non-covered Recipient Entity
Michigan Center Of Medical Research
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184307491
Principal investigator 1 Ipsen Pharma SAS $69.16 02/17/2025 Covered Recipient Teaching Hospital
Beaumont Health - Grosse Pointe
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305417
Principal investigator 1 Ipsen Pharma SAS $29.26 02/17/2025 Covered Recipient Teaching Hospital
Beaumont Health - Grosse Pointe
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305419
Principal investigator 1 Ipsen Pharma SAS $68.00 02/17/2025 Covered Recipient Teaching Hospital
Beaumont Health - Grosse Pointe
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305421
Principal investigator 1 Ipsen Pharma SAS $54.53 02/17/2025 Covered Recipient Teaching Hospital
Beaumont Health - Grosse Pointe
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305423
Principal investigator 1 Ipsen Pharma SAS $66.67 02/17/2025 Covered Recipient Teaching Hospital
Beaumont Health - Grosse Pointe
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305425
Principal investigator 1 Ipsen Pharma SAS $174.23 02/17/2025 Covered Recipient Teaching Hospital
Beaumont Health - Grosse Pointe
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305427
Principal investigator 1 Ipsen Pharma SAS $697.37 02/17/2025 Covered Recipient Teaching Hospital
Beaumont Health - Grosse Pointe
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305429
Principal investigator 1 Ipsen Pharma SAS $174.23 02/17/2025 Covered Recipient Teaching Hospital
Beaumont Health - Grosse Pointe
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305431
Principal investigator 1 Ipsen Pharma SAS $69.16 02/17/2025 Covered Recipient Teaching Hospital
Beaumont Health - Grosse Pointe
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305433
Principal investigator 1 Ipsen Pharma SAS $66.67 02/17/2025 Covered Recipient Teaching Hospital
Beaumont Health - Grosse Pointe
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305435
Principal investigator 1 Ipsen Pharma SAS $54.53 02/17/2025 Covered Recipient Teaching Hospital
Beaumont Health - Grosse Pointe
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305437
Principal investigator 1 Ipsen Pharma SAS $159.60 02/17/2025 Covered Recipient Teaching Hospital
Beaumont Health - Grosse Pointe
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305439
Principal investigator 1 Ipsen Pharma SAS $174.23 02/17/2025 Covered Recipient Teaching Hospital
Beaumont Health - Grosse Pointe
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305441
Principal investigator 1 Ipsen Pharma SAS $500.00 02/17/2025 Covered Recipient Teaching Hospital
Beaumont Health - Grosse Pointe
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305443
Principal investigator 1 Ipsen Pharma SAS $270.68 02/17/2025 Covered Recipient Teaching Hospital
Beaumont Health - Grosse Pointe
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305445
Principal investigator 1 Ipsen Pharma SAS $212.80 02/17/2025 Covered Recipient Teaching Hospital
Beaumont Health - Grosse Pointe
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305447
Principal investigator 1 Ipsen Pharma SAS $212.80 02/17/2025 Covered Recipient Teaching Hospital
Beaumont Health - Grosse Pointe
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305449
Principal investigator 1 Ipsen Pharma SAS $66.67 02/17/2025 Covered Recipient Teaching Hospital
Beaumont Health - Grosse Pointe
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305451
Principal investigator 1 Ipsen Pharma SAS $54.53 02/17/2025 Covered Recipient Teaching Hospital
Beaumont Health - Grosse Pointe
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305453
Principal investigator 1 Ipsen Pharma SAS $29.26 02/17/2025 Covered Recipient Teaching Hospital
Beaumont Health - Grosse Pointe
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305455
Principal investigator 1 Ipsen Pharma SAS $2,000.00 02/17/2025 Covered Recipient Teaching Hospital
Beaumont Health - Grosse Pointe
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305457
Principal investigator 1 Ipsen Pharma SAS $159.60 02/17/2025 Covered Recipient Teaching Hospital
Beaumont Health - Grosse Pointe
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305459
Principal investigator 1 Ipsen Pharma SAS $212.80 02/17/2025 Covered Recipient Teaching Hospital
Beaumont Health - Grosse Pointe
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305461
Principal investigator 1 Ipsen Pharma SAS $29.26 02/17/2025 Covered Recipient Teaching Hospital
Beaumont Health - Grosse Pointe
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305463
Principal investigator 1 Ipsen Pharma SAS $159.60 02/17/2025 Covered Recipient Teaching Hospital
Beaumont Health - Grosse Pointe
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305465
Principal investigator 1 Ipsen Pharma SAS $1,323.35 02/17/2025 Non-covered Recipient Entity
Michigan Center Of Medical Research
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184307489
Principal investigator 1 Ipsen Pharma SAS $1,436.40 01/29/2025 Non-covered Recipient Entity
Michigan Center Of Medical Research
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184307487
Principal investigator 1 Ipsen Pharma SAS $500.00 01/06/2025 Covered Recipient Teaching Hospital
Beaumont Health - Grosse Pointe
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305349
Principal investigator 1 Ipsen Pharma SAS $1,500.00 01/02/2025 Covered Recipient Teaching Hospital
Beaumont Health - Grosse Pointe
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305351
Principal investigator 1 Ipsen Pharma SAS $2,000.00 01/02/2025 Covered Recipient Teaching Hospital
Beaumont Health - Grosse Pointe
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184305353